Vandana Singh
·
September 10, 2025
Benzinga
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices.
read more
September 5, 2025
August 10, 2025
Bloomberg
August 14, 2025
August 7, 2025